Dihydroartemisinin engages liver fatty acid binding protein and suppresses metastatic hepatocellular carcinoma growth.

Mei-Ling RuanYungen Liu Chunlei ZhangXiaowen MaoDi HuChun-Nam Lok Judy Wai Ping Yam Chi-Ming Che

Published in: Chemical communications (Cambridge, England) (2023)

Dihydroartemisinin non-covalently binds liver fatty acid binding protein (FABP1) with micromolar affinity, acts as a FABP1-dependent peroxisome proliferator-activated receptor alpha agonist and inhibits metastatic hepatocellular carcinoma growth.

Keyphrases

binding protein
fatty acid
squamous cell carcinoma
small cell lung cancer
signaling pathway
drug administration
mass spectrometry